Logo

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

Share this

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

Shots:

  • mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4-000L CSR Bioreactor
  • The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site
  • The 4-000L volume & performance comparable to stainless steel systems will enable mAbxience to improve flexibility- productivity and efficiency. The CSR bioreactor design also allows for seamless scale-up and transfer of cell culture processes- thereby reducing time to market for mAbxience’s products

  Ref: Businesswire | Image: mAbxience

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions